Skip to main content
Sign In

Bradley Haverkos, MD, MPH

Bradly Haverkos, MD, MPH
Bradley Haverkos, MD, MPH
University of Colorado School of Medicine
  • Assistant Professor of Medicine


Contact information​

Anschutz Medical Campus
1665 Aurora Ct, MS F754
Aurora, CO  80045


​Dr. Haverkos completed his bachelor’s degree at Miami University in Ohio. This was followed by receipt of a combined MD/MPH degree at Wright State University in Dayton, Ohio as part of the Boonshoft School of Medicine Physician Leadership Development Program. He moved to the University of Illinois in Chicago for his residency in Internal Medicine. 

He then completed his fellowship training in Hematology and Oncology at Ohio State University, where he also completed a Master’s degree in Medical Science and a NIH sponsored post-doctoral fellowship with an emphasis on immunology, virology, biostatistics, and clinical trial design. In 2015 he joined the lymphoma and BMT program at the University of Colorado.

Dr. Haverkos is a principle investigator of multiple early-phase clinical trials. He has published and presented his research at the national and international level. He also serves as a reviewer for a number of medical journals and is a member on multiple professional organizations. 

  • ​​Miami University, BA 1999-2003

  • Boonshoft School of Medicine at Wright State University, MD 2004-2009

  • Wright State University, MPH 2004-2009

  • University of Illinois in Chicago Internal Medicine Residency, 2009-2012

  • Ohio State Oncology Fellowship, 2012-2014

  • Postdoctoral Fellowship at Ohio State University, 2013-2015

  • Ohio State University, MS 2015

​Dr. Haverkos’ research focuses on developing novel management and treatment strategies in aggressive lymphoma subtypes with a focus on mature T and NK cell lymphoproliferative disorders (LPDs), including T-cell lymphomas. He collaborates with multiple laboratories with the goal of improving our understanding on the etiopathogenesis of T and NK/T-cell LPDs. 

He aims to translate discoveries grounded in this translational research into early phase clinical trials, which will lead to better patient outcomes. Recently, his research efforts center on identifying markers that prognosticate and predict response to specific therapies. He is also interested in improving clinical practice guidelines for patients with blood cancers.​

​Yuan, S., Yu, J, Haverkos, B, & Su, H. Remission of an extensively pre-treated relapsing/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy. Leuk Lymphoma. 2016 Jan 6:1-3.

Haverkos BH, Gru AA, Freud AG, Hastings J, Nowacki NB, Barrionuevo C, Vigil CE, Rochford R, Natkunam Y, Baiocchi RA, et al. The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment. Curr Hematol Malig Rep. 2015 Oct 8. *Co-author

Haverkos, B., Tyler, K., Kartono, F., Frederickson, J., Elkins, C., Peters, S., Zhang, X., Wong, H., & Porcu, P. Presentation, management, and experience in treating primary cutaneous B-cell lymphoma in the Multimodality Cutaneous Lymphoma Clinic at the Ohio State University. Oncologist. 2015.

Haverkos, B., Tyler, K., Hu, Eileen, Philip, R., Gru, A., Welliver, M., Mishra, A., Wong, H., & Porcu, P. The role of an integrated multidisciplinary clinic in the management of patients with cutaneous lymphoma. Frontiers Oncol. 2015 Jun 17;5:136. *Co-author

Roddy, J., Haverkos, B., McBride, A., Leininger, K., Andritsos, L., & Devine, S. Tocilizumab in the Treatment of Steroid Refractory Graft Versus Host Disease: A Single Institutional Experience. Leukemia & Lymphoma. 2015.

Kaffenberger, B., Haverkos, B., Tyler, K., Porcu, P., Wong, H., & Gru, A. Extranodal Marginal Zone Lymphoma (MALT) - Like Presentations of Angioimmunoblastic T-cell lymphoma: A T-cell lymphoma masquerading as a B-cell lymphoproliferative disorder. American Journal of Dermatopathology. 2014.

Haverkos, B., Sborov, D., & Harris, P. A review of investigational cancer drugs targeting cell metabolism in clinical development. Expert Opinion on Investigational Drugs. 2014 Sep 16:1-16. *Co-author

Haverkos, B. McBride, A., O’Donnell, L., Scholl, D. Whittaker, B., Vasu, S. Penza, S., Andritsos, L., Devine, S., & Jaglowski, S. An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor. Bone Marrow Transplant. May 5, 2014.

Haverkos, B., Oza, V., Johnson, A., Walker, J., & Shan’ah, A. Rare Presentation of Post-transplant Lymphoproliferative Disorder Isolated to Gastroesophageal Junction. World Journal of Gastrointestinal Oncology. 2013 Dec 15;5(12):230-4.